+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CoMentis specializes in the development of small-molecule drugs to treat neurovascular diseases with a focus on Alzheimer's disease and schizophrenia. They cover the research and development spectrum from initial drug design through manufacturing and clinical trials. The company, with headquarters in South San Francisco, was formed by the merger of Zapaq, Inc. and Athenagen, Inc. in 2006. It is also working on nicotinic acetylcholine receptor modulators for the treatment of cognitive disorders.